Table 2.
Description of multiresistant bacteria.
| Multiresistant bacteria | Resistance to antibiotics |
|---|---|
| Escherichia coli (N = 7/19) | Ampicillin, cefalotin, ciprofloxacin, nalidixic acid, norfloxacin, ofloxacin, ticarcillin |
|
| |
|
Enterobacter cloacae (1) (N = 15/19) |
Amoxicillin/clavulanic acid, ampicillin, cefalotin, cefotaxime, cefoxitin, ceftazidime, ciprofloxacin, gentamicin, nalidixic acid, netilmicin, nitrofurantoin, norfloxacin, ofloxacin, ticarcillin, tobramycin |
|
| |
|
Enterobacter cloacae (2) (N = 6/19) |
Amoxicillin/clavulanic acid, ampicillin, cefalotin, cefotaxime, nalidixic acid, norfloxacin |
|
| |
|
Klebsiella pneumoniae (1) (N = 8/19) |
Ampicillin, ciprofloxacin, gentamicin, nalidixic acid, nitrofurantoin, norfloxacin, ofloxacin, ticarcillin |
|
| |
|
Klebsiella pneumoniae (2) (N = 14/19) |
Amoxicillin/clavulanic acid, ampicillin, cefalotin, cefotaxime, ceftazidime, ciprofloxacin, nalidixic acid, netilmicin, nitrofurantoin NCCLS, norfloxacin, ofloxacin, ticarcillin, tobramycin, trimeth-sulfamethoxazole |
|
| |
|
Klebsiella pneumoniae (3) (N = 17/19) |
Amikacin, amoxicillin/clavulanic acid, ampicillin, cefalotin, cefotaxime, ceftazidime, ciprofloxacin, gentamicin, nalidixic acid, netilmicin, nitrofurantoin, norfloxacin, ofloxacin, piperacillin/tazobactam, ticarcillin, tobramycin, trimethoprim/sulfamethoxazole |
|
| |
| Pseudomonas aeruginosa (N = 13/18) | Aztreonam, cefepime, ceftazidime, ciprofloxacin, imipenem, meropenem, minocycline, pefloxacin, piperacillin, piperacillin/tazobactam, ticarcillin, ticarcillin/clavulanic acid, trimethoprim/sulfamethoxazole |
|
| |
| Staphylococcus aureus (N = 4/22) | Benzylpenicillin, kanamycin, oxacillin, tobramycin |
|
| |
| Staphylococcus epidermidis (N = 9/22) | Benzylpenicillin, erythromycin, gentamicin, kanamycin, lincomycin, oxacillin, pristinamycin, quinupristin, tobramycin |
This table completes the information shown in Figure 6. The letter, N, corresponds to the number of resistant antibiotics in comparison with the total number of antibiotics tested against the bacterial strains. The inhibition area (cm2) of lauryl-PLL is shown at the concentration of grafted lauric acid, 10−4 M.